Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.01 USD

16.01
12,370,961

+0.30 (1.91%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $16.05 +0.04 (0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (164 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sumit Singh headshot

Pick These 4 Low P/CF Stocks for a Balanced Portfolio in 2H

by Sumit Singh

Investment in stocks made on diligent value analysis is usually considered one of the best practices. In value investing, investors pick stocks that are cheap but fundamentally sound.

Kinjel Shah headshot

Choose These 5 Price-to-Book Value Stocks for High Returns

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

Zacks Equity Research

Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (TEVA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Zacks Equity Research

Novartis Discontinues HCQ Study Due to Enrollment Challenges

by Zacks Equity Research

Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.

Kinjel Shah headshot

FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus

by Kinjel Shah

The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.

Zacks Equity Research

Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (TEVA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $11.25, moving -0.71% from the previous trading session.

Zacks Equity Research

Emergent (EBS) Down on Unfavorable Patent Ruling on Narcan

by Zacks Equity Research

Emergent's (EBS) stock falls after a district court rules against the patent litigation on its Narcan nasal spray product. The court ruled in favor of Teva Pharmaceuticals, the defendants.

Zacks Equity Research

Novartis' sBLA for Ofatumumab Gets Extended Review From FDA

by Zacks Equity Research

The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.

Zacks Equity Research

Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Can Teva (TEVA) Return to Growth in This Year or Next?

by Zacks Equity Research

Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.

Zacks Equity Research

Is Teva Pharmaceutical Industries Ltd (TEVA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales

by Zacks Equity Research

Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.

Zacks Equity Research

Teva (TEVA) Q1 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Teva beats estimates for earnings and sales in first-quarter 2020. It maintains its previously issued guidance for 2020. Stock up.

Zacks Equity Research

Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $10.84, marking a +1.12% move from the previous day.

Zacks Equity Research

Is a Beat in Store for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Equity Research

Lilly (LLY) Q1 Earnings Beat, Coronavirus May Mar Profits

by Zacks Equity Research

Eli Lilly (LLY) beat estimates for both earnings and sales in the first quarter of 2020. However, the company warns that coronavirus-related uncertainty may hurt financial results in 2020 and beyond.

Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $9.54 in the latest trading session, marking a +0.85% move from the prior day.

Zacks Equity Research

Novartis Terminates Sale of Sandoz Dermatology Business

by Zacks Equity Research

Novartis (NVS) terminates sale of Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

Zacks Equity Research

Amarin's Stock Plunges Following Unfavorable Patent Ruling

by Zacks Equity Research

Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.